http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 03:33:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html <p>Neurocrine Biosciences has received U.S. Food and Drug Administration acceptance of an Investigational New Drug application for a Phase 2 study of NBI-1117567, an oral muscarinic M1 preferring agonist being evaluated for Alzheimer's cognition, according to a statement from Nxera Pharma Co., Ltd. (TSE: 4565).</p> <p>The IND acceptance triggers a $10 million milestone payment from Neurocrine to Nxera, which the company expects to recognize as revenue in Q3 FY2026.</p> <p>NBI-1117567 was discovered by Nxera using its NxWave drug discovery platform and licensed to Neurocrine under a collaboration agreement signed in November 2021. Under that agreement, Nxera is eligible to receive up to http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html Wed, 26 Aug 2026 03:33:23 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html <p>Neurocrine Biosciences has received U.S. Food and Drug Administration acceptance of an Investigational New Drug application for a Phase 2 study of NBI-1117567, an oral muscarinic M1 preferring agonist being evaluated for Alzheimer's cognition, according to a statement from Nxera Pharma Co., Ltd. (TSE: 4565).</p> <p>The IND acceptance triggers a $10 million milestone payment from Neurocrine to Nxera, which the company expects to recognize as revenue in Q3 FY2026.</p> <p>NBI-1117567 was discovered by Nxera using its NxWave drug discovery platform and licensed to Neurocrine under a collaboration agreement signed in November 2021. Under that agreement, Nxera is eligible to receive up to http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html Wed, 26 Aug 2026 03:33:23 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html <p>Neurocrine Biosciences has received U.S. Food and Drug Administration acceptance of an Investigational New Drug application for a Phase 2 study of NBI-1117567, an oral muscarinic M1 preferring agonist being evaluated for Alzheimer's cognition, according to a statement from Nxera Pharma Co., Ltd. (TSE: 4565).</p> <p>The IND acceptance triggers a $10 million milestone payment from Neurocrine to Nxera, which the company expects to recognize as revenue in Q3 FY2026.</p> <p>NBI-1117567 was discovered by Nxera using its NxWave drug discovery platform and licensed to Neurocrine under a collaboration agreement signed in November 2021. Under that agreement, Nxera is eligible to receive up to http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html Wed, 26 Aug 2026 03:33:23 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html <p>Neurocrine Biosciences has received U.S. Food and Drug Administration acceptance of an Investigational New Drug application for a Phase 2 study of NBI-1117567, an oral muscarinic M1 preferring agonist being evaluated for Alzheimer's cognition, according to a statement from Nxera Pharma Co., Ltd. (TSE: 4565).</p> <p>The IND acceptance triggers a $10 million milestone payment from Neurocrine to Nxera, which the company expects to recognize as revenue in Q3 FY2026.</p> <p>NBI-1117567 was discovered by Nxera using its NxWave drug discovery platform and licensed to Neurocrine under a collaboration agreement signed in November 2021. Under that agreement, Nxera is eligible to receive up to http://www.streetinsider.com/FDA/FDA+accepts+IND+for+Neurocrine%27s+NBI-1117567+Alzheimer%27s+Phase+2+study/26976410.html Wed, 26 Aug 2026 03:33:23 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Press+Releases/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html <ul><li style="margin-top:22pt; margin-bottom:0in;">NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package</li><li style="margin-top:22pt; margin-bottom:0in;">Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge, UK, </b><b>26 August</b><b> 202</b><b>6</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma%E2%80%99s+Partner+Neurocrine+Biosciences+Receives+IND+Acceptance+from+the+FDA+for+Phase+2+Study+of+NBI-1117567+for+Alzheimer%26apos%3Bs+Cognition/26976408.html Wed, 26 Aug 2026 03:33:00 -0400 4565 A.06822034 O.05105894 O.20026344 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html <p><strong>Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – </strong>Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.<br></br><br></br>The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. <br></br><br></br>The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&amp;A session. http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html Wed, 15 Jul 2026 05:13:00 -0400 4565 O.05105894 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html <p><strong>Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – </strong>Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.<br></br><br></br>The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. <br></br><br></br>The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&amp;A session. http://www.streetinsider.com/Press+Releases/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html Wed, 15 Jul 2026 05:13:00 -0400 4565 O.05105894 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html <p><strong>Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – </strong>Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.<br></br><br></br>The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. <br></br><br></br>The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&amp;A session. http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html Wed, 15 Jul 2026 05:13:00 -0400 4565 O.05105894 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html <p><strong>Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – </strong>Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026.<br></br><br></br>The Company will host a live webinar presentation with Chris Cargill (President, CEO), Hironoshin Nomura (CFO), Toshi Maeda (COO) and Patrik Foerch (CSO and President of Nxera Pharma UK), at 5:00 pm JST (9:00 am GMT) on Friday, 7 August 2026. <br></br><br></br>The webinar is open to all existing and potential investors as well as sell-/buy-side analysts and will consist of a presentation followed by a Q&amp;A session. http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+Webinar+for+Financial+Results+Presentation+-+2Q2026/26769903.html Wed, 15 Jul 2026 05:13:00 -0400 4565 O.05105894 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html <ul type="disc"><li style="margin-top:12pt;">This marks the fourth R&amp;D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration</li><li style="margin-top:12pt;">Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge and London, UK, 30 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&amp;D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html Tue, 30 Jun 2026 04:27:00 -0400 4565 O.05105894 http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html <ul type="disc"><li style="margin-top:12pt;">This marks the fourth R&amp;D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration</li><li style="margin-top:12pt;">Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge and London, UK, 30 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&amp;D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting http://www.streetinsider.com/Press+Releases/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html Tue, 30 Jun 2026 04:27:00 -0400 4565 O.05105894 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html <ul type="disc"><li style="margin-top:12pt;">This marks the fourth R&amp;D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration</li><li style="margin-top:12pt;">Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge and London, UK, 30 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&amp;D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html Tue, 30 Jun 2026 04:27:00 -0400 4565 O.05105894 http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html <ul type="disc"><li style="margin-top:12pt;">This marks the fourth R&amp;D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration</li><li style="margin-top:12pt;">Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales</li></ul> <p align="justify"><b>Tokyo, Japan and Cambridge and London, UK, 30 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a fourth R&amp;D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting http://www.streetinsider.com/Globe+Newswire/Nxera+Pharma+to+Receive+US%2410+Million+Milestone+Payment+from+AbbVie+under+Collaboration+Targeting+Neurological+Diseases/26708497.html Tue, 30 Jun 2026 04:27:00 -0400 4565 O.05105894 http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 10 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.</p> <p align="justify">OpenFold’s mission is provide researchers from academia and industry with access to http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html Wed, 10 Jun 2026 02:35:00 -0400 4565 A.02973684 A.42133989 O.00285735 O.05105894 O.10335760 http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 10 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.</p> <p align="justify">OpenFold’s mission is provide researchers from academia and industry with access to http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html Wed, 10 Jun 2026 02:35:00 -0400 4565 A.02973684 A.42133989 O.00285735 O.05105894 O.10335760 http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 10 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.</p> <p align="justify">OpenFold’s mission is provide researchers from academia and industry with access to http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html Wed, 10 Jun 2026 02:35:00 -0400 4565 A.02973684 A.42133989 O.00285735 O.05105894 O.10335760 http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 10 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.</p> <p align="justify">OpenFold’s mission is provide researchers from academia and industry with access to http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html Wed, 10 Jun 2026 02:35:00 -0400 4565 A.02973684 A.42133989 O.00285735 O.05105894 O.10335760 http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html <p align="justify"><b>Tokyo, Japan and Cambridge, UK, 10 June 2026</b> – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.</p> <p align="justify">OpenFold’s mission is provide researchers from academia and industry with access to http://www.streetinsider.com/Press+Releases/Nxera+Joins+OpenFold+AI+Research+Consortium+Alongside+Leading+Global+Pharmaceutical+and+AI+Companies+to+Accelerate+AI-enabled+Drug+Discovery/26625557.html Wed, 10 Jun 2026 02:35:00 -0400 4565 A.02973684 A.42133989 O.00285735 O.05105894 O.10335760